Talquetamab Combos Show Survival Benefit in r/r Myeloma

Interim findings from the phase 3 MonumenTAL-3 trial highlight overall and progression-free survival as well as response rates compared with standard therapy.
Medscape Medical News

source https://www.medscape.com/viewarticle/talquetamab-combinations-show-survival-benefit-r-r-myeloma-2026a1000k6r?src=rss